Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2017’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects

The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aeolus Pharmaceuticals Inc

Angion Biomedica Corp

Atox Bio Ltd

BCN Biosciences LLC

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

Cellphire Inc

Chrysalis BioTherapeutics Inc

Cleveland BioLabs Inc

Daiichi Sankyo Company Ltd

FirstString Research Inc

Foresee Pharmaceuticals LLC

Galera Therapeutics Inc

Genzyme Corp

GNI Group Ltd

Humanetics Corp

Insys Therapeutics Inc

Meabco A/S

Neumedicines Inc

Nohla Therapeutics Inc

Onconova Therapeutics Inc

Original BioMedicals Co Ltd

PharmaIN Corp

Pluristem Therapeutics Inc

RDD Pharma Ltd

Reata Pharmaceuticals Inc

RedHill Biopharma Ltd

RxBio Inc

Shuttle Pharmaceuticals LLC

SK Chemicals Co Ltd

Soligenix Inc

Synedgen Inc

Tonix Pharmaceuticals Holding Corp

TSRL Inc

viDA Therapeutics Inc

Windtree Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 9

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 20

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 24

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 31

Aeolus Pharmaceuticals Inc 31

Angion Biomedica Corp 31

Atox Bio Ltd 32

BCN Biosciences LLC 32

Bolder Biotechnology Inc 33

Cellerant Therapeutics Inc 33

Cellphire Inc 34

Chrysalis BioTherapeutics Inc 34

Cleveland BioLabs Inc 35

Daiichi Sankyo Company Ltd 35

FirstString Research Inc 36

Foresee Pharmaceuticals LLC 36

Galera Therapeutics Inc 37

Genzyme Corp 37

GNI Group Ltd 38

Humanetics Corp 38

Insys Therapeutics Inc 39

Meabco A/S 39

Neumedicines Inc 40

Nohla Therapeutics Inc 40

Onconova Therapeutics Inc 41

Original BioMedicals Co Ltd 41

PharmaIN Corp 42

Pluristem Therapeutics Inc 42

RDD Pharma Ltd 43

Reata Pharmaceuticals Inc 43

RedHill Biopharma Ltd 44

RxBio Inc 44

Shuttle Pharmaceuticals LLC 45

SK Chemicals Co Ltd 45

Soligenix Inc 46

Synedgen Inc 46

Tonix Pharmaceuticals Holding Corp 47

TSRL Inc 47

viDA Therapeutics Inc 48

Windtree Therapeutics Inc 48

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles 49

(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 49

A-02 - Drug Profile 50

AB-103 - Drug Profile 51

ABC-294640 - Drug Profile 54

AEOL-10171 - Drug Profile 61

Aerosurf - Drug Profile 62

amifostine - Drug Profile 67

amifostine - Drug Profile 68

AVMOC-001 - Drug Profile 69

BB-3 - Drug Profile 70

BBT-007 - Drug Profile 74

BBT-015 - Drug Profile 75

BBT-018 - Drug Profile 76

BBT-059 - Drug Profile 77

BCN-057 - Drug Profile 78

BIO-300 - Drug Profile 79

BMX-001 - Drug Profile 82

BPC-2 - Drug Profile 84

C-2E2 - Drug Profile 85

C-2E5 - Drug Profile 86

Cell Therapy for Acute Radiation Syndrome - Drug Profile 87

cerium oxide - Drug Profile 88

CLT-009 - Drug Profile 89

Des-Asp Angiotensin 1 - Drug Profile 90

DG-3 - Drug Profile 91

entolimod - Drug Profile 92

EWA-001 - Drug Profile 99

Fibrinoplate-S - Drug Profile 100

FP-045 - Drug Profile 101

Granexin - Drug Profile 102

HSJ-0017 - Drug Profile 104

JP4-039 - Drug Profile 105

LGM-2605 - Drug Profile 107

m-2A2 - Drug Profile 108

MDY-1001 - Drug Profile 109

molgramostim - Drug Profile 110

NAS-911 - Drug Profile 111

NMIL-121 - Drug Profile 113

omaveloxolone - Drug Profile 117

ondansetron hydrochloride - Drug Profile 120

ondansetron hydrochloride CR - Drug Profile 121

Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile 128

pirfenidone - Drug Profile 129

PLXR-18 - Drug Profile 131

Preimplantation Factor - Drug Profile 138

QR-205 - Drug Profile 139

RDD-2007 - Drug Profile 140

recilisib sodium - Drug Profile 141

Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 143

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 144

Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile 145

Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile 146

RP-239X - Drug Profile 147

RS-9 - Drug Profile 148

rusalatide acetate - Drug Profile 149

Rx-100 - Drug Profile 153

sargramostim - Drug Profile 155

SGX-201 - Drug Profile 158

SGX-202 - Drug Profile 159

SKI-2162 - Drug Profile 162

Small Molecule for Prostate Cancer, Asthma and Radiation Injury - Drug Profile 163

Small Molecule for Radiation Toxicity - Drug Profile 164

Small Molecule for Radiation Toxicity 1 - Drug Profile 165

Small Molecule to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile 166

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 167

SP-3001 - Drug Profile 168

ST-266 - Drug Profile 169

ST-7 - Drug Profile 172

SY-513 - Drug Profile 173

SYGN-305 - Drug Profile 174

SYGN-399 - Drug Profile 175

Thrombosomes - Drug Profile 176

TNX-701 - Drug Profile 177

TPO-7630 - Drug Profile 178

TPO-7640 - Drug Profile 180

VEDA-1209 - Drug Profile 181

VTI-1000 Series - Drug Profile 182

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 183

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 186

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 187

Featured News & Press Releases 187

Appendix 196

Methodology 196

Coverage 196

Secondary Research 196

Primary Research 196

Expert Panel Validation 196

Contact Us 196

Disclaimer 197

List of Tables

List of Tables

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Aeolus Pharmaceuticals Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Angion Biomedica Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Atox Bio Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by BCN Biosciences LLC, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Bolder Biotechnology Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Cellerant Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Cellphire Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Chrysalis BioTherapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Cleveland BioLabs Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by FirstString Research Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Galera Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Genzyme Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by GNI Group Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Humanetics Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Insys Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Meabco A/S, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Neumedicines Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Nohla Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Onconova Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Original BioMedicals Co Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by PharmaIN Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Pluristem Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by RDD Pharma Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Reata Pharmaceuticals Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by RedHill Biopharma Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by RxBio Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Shuttle Pharmaceuticals LLC, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by SK Chemicals Co Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Soligenix Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Synedgen Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by TSRL Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by viDA Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Windtree Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H1 2017 (Contd..2), H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports